Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of [14C]GZR18 in overweight/obese Chinese males
NCT07119450Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- May 2025
- Primary completion
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bofanglutide in obesity, sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Total radioactivity in blood at 1 year, Total radioactivity in plasma at 1 year and 6 more. Started May 2025; status: completed.
02
Drugs
bofanglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07119450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07119450.